Nephrogenous cyclic AMP (NcAMP), total cyclic AMP excretion (UcAMP), and plasma immunoreactive parathyroid hormone (iPTH), determined with a multivalent antiserum, were prospectively measured in 55 control subjects, 57 patients with primary hyperparathyroidism (1°HPT), and 10 patients with chronic hypoparathyroidism.
The development of a parametric expression for UcAMP was found to be critically important in the clinical interpretation of results for total cAMP excretion. Because of renal impairment in a large number of patients, the absolute excretion rate of cAMP correlated poorly with the hyperparathyroid state. Expressed as a function of creatinine excretion, UcAMP was elevated in 81% of patients with 1° HPT, but the nonparametric nature of the expression led to a number of interpretive difficulties. The expression of cAMP excretion as a function of glomerular filtration rate was developed on the basis of the unique features of cAMP clearance in man, and this expression, which provided elevated values in 51 A B S T R A C T Nephrogenous cyclic AMP (NcAMP), total cyclic AMP excretion (UcAMP), and plasma immunoreactive parathyroid hormone (iPTH), determined with a multivalent antiserum, were prospectively measured in 55 control subjects, 57 patients with primary hyperparathyroidism (10 HPT) , and 10 patients with chronic hypoparathyroidism.
In the group with 1°HPT, NcAMP was elevated in 52 patients (91%), and similar elevations were noted in subgroups of 26 patients with mild (serum calcium c 10.7 mg/dl) or intermittent hypercalcemia, 19 patients with mild renal insufficiency (mean glomerular filtration rate, 64 mllmin), and 10 patients with moderate renal insufficiency (mean glomerular filtration rate, 43 ml/min). Plasma iPTH was increased in 41 patients (73%).
The development of a parametric expression for UcAMP was found to be critically important in the clinical interpretation of results for total cAMP excretion. Because of renal impairment in a large number of patients, the absolute excretion rate of cAMP correlated poorly with the hyperparathyroid state. Expressed as a function of creatinine excretion, UcAMP was elevated in 81% of patients with 10 HPT, but the nonparametric nature of the expression led to a number of interpretive difficulties. The expression of cAMP excretion as a function of glomerular filtration rate was developed on the basis of the unique features of cAMP clearance in man, and this expression, which provided elevated values in 51 (89%) ofthe patients with 10 HPT, avoided entirely the inadequacies of alternative expressions.
Results for NcAMP and UcAMP in nonazotemic and azotemic patients with hypoparathyroidism confirmed INTRODUCTION The development of the immunoassay for parathyroid hormone (PTH)l in the mid-1960's (1) represented a distinct methodologic advance in the study of parathyroid physiology and pathophysiology. However, a number of technical and biologic difficulties, including the heterologous nature of the assays in current use (1, 2) and the heterogeneity of circulating forms of human PTH (3) (4) (5) (6) , have combined to restrict the availability and applicability of the technique. Although a partial resolution of these problems has been provided by the use of defined antisera, which recognize specific regions of the circulating peptides (2, 3, 5, 6) , there remains a need for a simple and readily standardizable parathyroid function test.
In the late 1960's, the actions of PTH were shown to be mediated by cyclic AMP (cAMP), and the effects of the hormone on the renal cortex were found to be associated with dramatic increases in the excretion of the nucleotide (7) (8) (9) (10) . Based on these findings, a number of laboratories have attempted to use measurements of cAMP excretion (UcAMP) diagnostically in patients with parathyroid disease, with varying success (11) (12) (13) (14) (15) (16) (17) (18) . The fact that this analysis has not gained widespread acceptance as a valid index of parathyroid function can be attributed principally to three aspects of the data base currently available: (a) the lack of a demonstrably parametric expression for total cAMP excretion, (b) the description of several clinical and (or) experimental circumstances, including renal impairment (11, 12, 19) and high extracellular calcium concentrations (20) , 1Abbreviations used in this paper: cAMP, cyclic AMP; which might interfere with the cAMP analyses or their interpretation, and (c) the alterations in plasma and (or) urinary cAMP which have been reported after pharmacologic doses of a number of agents (11, (21) (22) (23) (24) and the apparent increases in UcAMP which have been noted in several disorders other than primary hyperparathyroidism (1°HPT) (13, (25) (26) (27) . Thus, there has been reasonable doubt concerning the clinical specificity of in vivo measurements of cAMP.
That these potential problems in the performance and interpretation of clinical cAMP studies may be more apparent than real derives from the unique aspects of cAMP clearance and excretion in man (28) . Plasma cAMP is excreted by a process of simple glomerular filtration, and to this filtered load of the nucleotide is added a quantity of cAMP formed de novo in the kidney (nephrogenous cAMP). Nephrogenous cAMP (NcAMP): (a) is the only "pool" ofthe nucleotide easily quantified in vivo (28) , (b) reflects almost exclusively the effects of circulating PTH (9, 29) , and (c) appears to be added directly to the tubular urine (9, 10) , thus accounting for the magnitude, rapidity, and sensitivity of the PTH-induced changes in cAMP excretion. Although vasopressin also acts directly on a renal adenylate cyclase system (8, 30) , at physiologic concentrations it has little, if any, effect on cAMP excretion (13, 29, 31, 32) . Thus, the determination of NcAMP should provide a sensitive and specific assessment of parathyroid function, and several recent reports suggest that this measurement is extremely useful in the diagnosis of 10 HPT (33) (34) (35) Patients with hypoparathyroidism. 10 patients with chronic hypoparathyroidism (2 idiopathic and 8 postoperative) were studied. Nine of the patients were receiving longterm vitamin D and calcium supplements and were deliberately being maintained with a relatively low serum calcium (mean-+SD, 7.9±0.8 mg/dl). There were four women and six men, and the mean age was 44 yr. 9 of the 10 patients had significant medical illness other than hypoparathyroidism for which they were taking a variety of medications.
Patients with hyperparathyroidism. 57 patients with 1°HPT were studied. There were 35 women (age range 9-78 yr, mean 51 yr) and 22 men (age range 16-74 yr, mean 46 yr). 23 were patients at the National Institutes of Health, and the remaining 34 patients were at the Massachusetts General Hospital.
For purposes of discussion, the patients have been divided into two groups. 40 patients were considered to have a "definite" diagnosis of 1°HPT based on one of the following criteria: (a) neck exploration with tissue confirmation (adenomas in 18 patients and hyperplasia in 11 patients), (b) familial hyperparathyroidism with tissue confirmation in at least one family member (7 patients), or (c) significant step-up in iPTH during neck vein catheterization (36) in a hypercalcemic patient (4 patients). An additional 17 patients were considered to have "clinical" diagnoses of 10 HPT based on documented hypercalcemia on a minimum of two determinations of serum calcium and exclusion of other causes of hypercalcemia by thorough clinical and biochemical evaluation. 14 of these 17 patients had clinical and (or) chemical histories suggestive of 10 HPT of greater than 1-yr duration. Approximately one-half of these 57 patients had significant additional medical illness for which they were receiving a variety of medications.
Five patients included in the "definite" subgroup of patients were members of two generations of a single kindred regarded as having "familial hypocalciuric hypercalcemia" (patients 36-40, Table II ). This kindred had quite severe, but relatively asymptomatic, hypercalcemia, and a histologically hyperplastic gland had been removed from one of the patients. However, determinations of iPTH and NcAMP were repeatedly normal in these 5 patients, in contrast to the frank elevations in one or both of these analyses which were noted in each of the remaining 52 patients. This kindred was included in this series because of the prospective nature of the study, and its members are referred to as "biochemically normal" in the text below. Several patients from other kindreds with familial hyperparathyroidism were also studied (Table  II) and demonstrated clearcut biochemical evidence of disease.
Study protocol
All patients and control subjects underwent an identical study protocol. Urine specimens were collected over a 2-, 3-, or 4-h period between 6 a.m. and 12 noon. Midpoint blood samples were drawn for the analysis of plasma cAMP and iPTH and serum calcium and creatinine. Approximately 1-ml aliquots of the urine specimens were taken, and the remaining urine was pooled into an ongoing 24-h collection.
During the morning collection periods, fluid intake was encouraged to ensure adequacy of the collections (urine flow averaged 1.5-2 ml/min), beverages containing methyl xanthines were excluded, and activity was limited to bed, chair, and bathroom privileges. Although the state of hydration (13, 29, 31, 32) or the consumption of methyl xanthines (29, 37) do not appear to influence cAMP excretion, physical activity has been reported to increase plasma cAMP (25) Both plasma iPTH (3, 38, 39) and plasma and urinary cAMP (18, 29, 37) have been reported to exhibit a diurnal variation, although in each case there is disagreement as to the exact pattern and extent of variation. In 52 patients, plasma cAMP was determined between 8 and 9 a.m. and again between 11 a.m. and 12 noon. The results±SEM for these 104 plasma samples were 15.91±0.51 and 15.55±0.47 nM, respectively. Serial clearance determinations (two or three clearance periods) were performed in 15 control subjects and 8 patients with 1°HPT between 6 a.m. and 12 noon and the results were within the variability of the methodology. Finally, in a series of five normal subjects and two patients with 1°HPT in whom no attempt was made to control diet or activity, cAMP excretion, expressed as nanomoles per 100 glomerular filtrate (GF), varied by only 10-24% from mean values in 12 sequential 4-h collections.
The iPTH and cAMP data represent the mean of multiple measurements in almost every patient and control subject. Collection and preparation of samples Urinie. Urine samples were collected into 6 N HCl (1 ml/h of collectioni), aliquoted, and frozen at -200C until analyzed.
After the addition of about 1 pmol of [3H]cAMP, aliquots of the urine samples (containing approximately 100 pmol cAMP) were applied to 5 x 0.5-cm columns of AG1-X8 (formate form, 200-400 mesh) prepared in Pasteur pipettes, washed with 10 ml water, and eluted with 1.0 N formic acid. The cAMP eluates (2nd through 11th ml) were collected in glass scintillation vials, lyophilized, dissolved in 1 ml water, and assayed. Recovery averaged approximately 80% (range 65-91%). We have retrospectively reassayed 100 nonchromatographed samples from 70 patients after appropriate dilution and have found excellent general agreement (within 10-15%) with the values for cAMP content after chromatography.
Plasma. Blood samples were drawn into chilled heparinized tubes for iPTH and into EDTA tubes for cAMP (vacutainer tube 3,200 QS containing 15 mg of tripotassium EDTA in 0.1 ml solution). The samples were centrifuged at 1,600-2,000 g for 20 min at 4°C, and the plasma was aspirated, with particular care to leave the buffy coat undisturbed in the cAMP sample. Plasma was stored at -20°C until analysis. Approximately 1 pmol [3H]cAMP was added to 3-ml samples of plasma (containing about 45 pmol cAMP), and the samples were deproteinized by the addition of 7 ml of 5.7% TCA. The extracts were neutralized with potassium hydroxide, with bromthymol blue as an internal indicator, and applied to 7.5 x 0.8-cm columns ofAG 1-X8 (formate form, 200-400 mesh) prepared in disposable chromaflex columns. The columns were washed with 10 ml water and eluted with 1.0 N formic acid, cAMP appearing in the 5th through 10th ml (insoluble material appearing in the first 4 ml was avoided by discarding this fraction). The eluates were collected in glass scintillation vials, lyophilized, dissolved in 500 ,ul water, and aliquots were counted for recovery (which averaged about 60%, range 53-71%). Earlier attempts to use AG 50-X8 chromatography revealed that eluates from this resin gave a variable blank in our assay, which could contribute significant error in the assay of plasma samples.
Analyses
Plasma iPTH was measured in previously unthawed samples at the Nichols Institute for Endocrinology, San Pedro, Calif. This method (40) employs a guinea-pig anti-bovine antiserum (GP-101), bovine 1251-PTH, a standard pool of serum from patients with hyperparathyroidism (results expressed in equivalent units), and a second antibody for separating bound and free hormone. Antiserum GP-101 is multivalent and has approximately equal affinity for the amino-terminal and carboxy-terminal sites of the human hormone.2 Samples were assayed in triplicate, and control tubes (lacking antiserum) were run in duplicate for each unknown for detection of nonspecific binding. The limits of detection (approximately 25 ,uleq/ml) were reported as 10% displacement of iodinated ligand; the upper limits of normal (90 ,uleq/ml) corresponded to 25-30% displacement. With serum pools of 60, 103, and 743 plieq/ml, the interassay coefficients of variation were 19% (n = 20), 14% (n = 11), and 9% (n = 15), respectively. cAMP was measured by a modification of the protein-binding assay of Gilman (41) . The assay was designed to optimize cAMP measurement between 0.5 and 10 pmol (approximately 20 and 80% displacement, respectively); about 90% saturation was achieved by the addition of 1-1.5 pmol of [3H]cAMP. Plasma and urine samples from a given patient were always assayed simultaneously. The interassay coefficient ofvariation for urine specimens is 10.2% (58 assays) and for plasma samples, 15.4% (24 assays).
Urinary creatinine was measured by the method of Bonses and Taussky (42). Other routine analyses were determined by standard techniques in the clinical chemistry laboratories of the Clinical Center and the Massachusetts General Hospital.
In the early phases of this study, it became clear that the serum creatinine was the least reliable of the various analyses required for the calculation of NcAMP (and cAMP excretion, expressed as a function of GFR). This potential problem can be minimized by the use of the mean of several measurements of serum creatinine in each study.
Expression and calculation of cAMP data NcAMP was expressed: (a) as an absolute rate (nanomoles per minute), (b) in relative terms, provided by the clearance ratio (cAMP:creatinine), and (c) as a function of GFR, as given by the expression:
Ccr where C, P, U, and V represent the conventional symbols for clearance, plasma and urinary concentration, and urine flow rate; cA is cyclic AMP and cr is creatinine. ,uleq/ml) were derived from the range of observed values in 150 normal subjects (40) . 95% of the subjects in the control group (n = 55) of this study had levels of iPTH c 90 ,uleq/ml (mean±+1.645 SD), and two subjects had undetectable (nd) levels.
expression are nmol/min per 100 ml GFR, or more correctly, nmol/100 ml GF (where GF is glomerular filtrate UcAMP, expressed as a function of GFR (nanomoles per 100 ml GF), may be conveniently computed by the product of the serum creatinine and UcAMP (in nanomoles per milligram creatinine), and NcAMP (nanomoles per 100 ml GF) may be easily obtained by subtracting the plasma cAMP concentration (in nanomoles per deciliter) from this value; these simple calculations can be applied to spot sample collections.
Statistical analysis
The cAMP and iPTH analyses in the control group appeared to be normally distributed, and these data were treated with conventional statistics. In the patients with 1°HPT, however, both parameters were positively skewed; no attempt was made to normalize these data.
RESULTS
Plasma PTH. The results for plasma iPTH are shown in Fig. 1 and Tables I and II. In the group with 10 HPT, iPTH was increased (>90 ,ueq/ml) in 41 (73%) of the 56 patients in whom it was measured. Excluding the 5 patients who were "biochemically normal" (see Methods), iPTH was increased in 80% of these patients. Tables I and II , expressed: (a) in relative terms (as the clearance ratio, cAMP:creatinine), (b) as an absolute rate (nanomoles per minute), and (c) as a function ofGFR (nanomoles per 100 ml GF).
In azotemic and nonazotemic patients with chronic hypoparathyroidism, values for the clearance ratio clustered around unity, with a mean of 1.23±0.09 (±SD) and a range of observed values of 1.08-1.36. In the control group, the mean clearance ratio was 2.01±0.43, with 95% of values falling below 2.72. The clearance ratio was greater than 2.72 in 52 of the patients with 10 HPT (91% ).
19 patients with 10 HPT had coincident mild renal insufficiency (mean GFR 64 ml/min, range 52-80 ml/min), and an additional 10 patients had moderate renal insufficiency (mean GFR 43 ml/min, range 30-50 ml/min). Although the absolute rate of NcAMP production (nanomoles per minute) correlated poorly with the hyperparathyroid state in these patients ( Fig. 2 and Table II), the clearance ratio was greater than 2.72 in 28 of these 29 patients. Thus, there was a clear parallel between the decreases in cAMP clearance and creatinine clearance in the patients with 10 HPT and renal insufficiency (Table II) and, therefore, an almost linear relationship between GFR and the ability to generate NcAMP in these patients (Fig. 2) .
These findings indicated that NcAMP might parametrically be expressed as a function of GFR, and in Fig. 3 , NcAMP is represented as nanomoles per 100 ml GF. NcAMP was low in the patients with chronic hypoparathyroidism (0.40±0.20 nmol/100 ml GF, mean±SD). In the control group, NcAMP was 1.55±0.63 nmol/100 ml GF (mean±SD), with 95% of values below 2.59 nmol/100 ml GF. In the group with 10 HPT, NcAMP was greater than 2.59 nmol/100 ml GF in 52 patients (91%), and all 29 patients with 10 HPT and renal impairment (identified in Fig. 3 ) displayed abnormally high values. Only the five familial patients classified as "biochemically normal" (patients 36-40, Table II ) displayed normal NcAMP. Excluding patients with moderate azotemia (GFR c 50 ml/min), there was a positive correlation (r = +0.40) between NcAMP and iPTH in the group with 10 HPT. Eight control subjects with renal impairment (mean GFR 65 ml/min, range 42-80 ml/min) had slightly higher mean values for iPTH (65 ,uleq/ml) and NcAMP (1.90 nmol/100 ml GF) than the general control population.
In 26 of the 57 patients with 10 HPT, the hypercalcemia was mild and (or) intermittent, yet the disease in these patients was not "mild" in terms of biochemical documentation; both iPTH (above 90 ,uleq/ml in 84%) and NcAMP (abnormal in 100%) were elevated in the great majority ofthese patients, and the biochemical abnormalities in some patients were striking (Table  II) Lnts from a kindred found to be "biochemically nor-HPT displayed "normal" UcAMP as a results of high depicted by open circles. There was a clear parallel levels of creatinine excretion (e.g., patient 22, Table  between cAMP clearance and creatinine clearance in the patients with 10 HPT and mild or moderate renal impairment (mean respective cAMP and creatinine clearances in the patients with mild azotemia were 232 and 64 ml/min and, in the patients with moderate azotemia, 153 and 43 ml/min). Excluding the patients with severe biochemical disease and those who were "biochemically normal," there was a linear correlation between NcAMP (nanomoles per minute) and GFR (r = +0.47).
NcAMP (r = +0.33) in the patients with 10 HPT (excluding patients 36-40 in Table II) .
Total cAMP excretion. UcAMP during the clearance periods, expressed as: (a) a rate (nanomoles per minute), (b) a function of creatinine excretion (nanomoles per milligram creatinine), and (c) a function of GFR (nanomoles per 100 ml GF), is shown in Fig. 4 and in Tables I and II. As expected, when expressed in absolute terms (nanomoles per minute), UcAMP Table II ). (c the mean UcAMP was low in the patients v hypoparathyroidism (2.08±0.72 nmol/mg mean±SD), results varied over greater tha range (from 0.72 nmol/mg creatinine in a patient to 3.61 nmol/mg creatinine in a co tient with low creatinine excretion). A partial, but artificial, solution to the i problems inherent in the expression may I by employing different male and female co] (Table I) .
Based on the unique features of cAMP c man (28) , both the filtered and nephrog ponents of cAMP excretion would be prec functions (direct or indirect) of the GF: data in this series readily confirmed this The data relating NcAMP to GFR is presei 2. Fig. 5 (1.83-4 .55 nmol/100 ml GF, with 95% of subjects excreting less than 4.31 nmol/100 GF), and there were no differences between male and female control subjects (Table I) . (b) 51 (89%) of the patients with 1°HPT excreted more than 4.31 nmol/100 ml GF of the nucleotide, and the increased UcAMP in these patients was real rather than apparent (Fig. 4 and Table II ). All HyperPT patients with "normal" UcAMP also had "normal" ,in the con-iPTH and were in the "definite" subgroup of patients The relationship between GFR and the filtered load ofcAMP in patients and control subjects with and without renal impairment. The figure depicts 79 patients and control subjects with normal renal function (GFR 108+16 ml/ min, mean+SD) and a mean filtered load of cAMP of 1.72 +0.41 nmol/min (±SD) and 46 patients with mild to moderate azotemia (GFR 56+15 ml/min, mean+SD) and a mean filtered load of the nucleotide of 1.08+0.29 nmol/min (+SD). Expressed as a function of GFR, the mean (±SD) filtered loads in the azotemic and nonazotemic patients were 1.92±0.45 and 1.59+0.30 nmol/100 ml GF, respectively. with 10 HPT (Table II) . (c) UcAMP was appropriately elevated in all patients with 10 HPT and mild or moderate renal impairment (identified in Fig. 4 ). (d) The patients with hypoparathyroidism excreted 2.16 +0.38 nmol/100 ml GF of cAMP (mean+SD), with a relatively narrow range of values (1.52-2.83 nmol/ 100 ml GF).
The data from the 24-h samples provided findings essentially identical to those noted above (Tables I and  II , the values expressed as a function of GFR are not shown). The 24-h analyses did not identify abnormalities in patients with 1°HPT who demonstrated normal UcAMP during the clearance periods.
DISCUSSION
Immunoassay data. Our iPTH data are consonant with those of other laboratories employing multivalent antisera (2, 43) but do not provide the 90% or greater increases in iPTH in patients with 10 HPT noted by some investigators with antisera reported to be primarily carboxyl specific (3, 5, 6, 38) . However, the present method remains very useful clinically, providing accurate diagnostic information in the great majority of patients with 10 HPT when results are discriminated as a function of serum calcium in the patients. The detectable iPTH in a number of the patients with hypoparathyroidism may have derived from some residual parathyroid function in patients whose serum calcium was deliberately being kept low (7.9±0.8 mg/dl, mean±SD).
Expression of cAMP data. The clearance ratio (cAMP:creatinine) is the simplest expression of NcAMP and provides accurate quantitative information under most circumstances. However, as a relative expression, this ratio is subject to quantitative variation resulting from differences in plasma levels of cAMP among individuals. The biological variables which alter plasma cAMP and which must be recognized as potential influences on the clearance ratio are physical activity (25) , severe renal failure (9, 44), and adrenergic discharge (21, 25 pressed on this basis gave a somewhat narrower normal range and a better apparent segregation of patients with 1°HPT from normal (9, 11-18, 33-35, 37) . It is of interest that in most of these studies, as in this series, expressing UcAMP as a function of creatinine excretion led to a mean decrease in values from control subjects and a mean increase in values from patients with 10 HPT, findings which could only have resulted from differences in creatinine excretion between the control and diseased populations. An additional, and extremely important, example of the potential hazard of expressing results on this basis is the inherent nonspecificity of this expression. That is, it is self-evident that a reduction in creatinine excretion accompanies any disease process with a significant wasting and (or) neuromuscular component and that this occurs independent of the variables which control cAMP excretion. In our experience, this nonparametric feature accounts entirely for the "apparent" increases in UcAMP which have been reported in patients with thyrotoxicosis (26, 27, 45) , the syndrome of inappropriate antidiuretic hormone secretion (13) , and the carcinoid syndrome (13) . Expressed parametrically (nanomoles per 100 ml GF), UcAMP is perfectly normal in these patients (29) .
The expression of UcAMP as a function of GFR is eminently rational, based on the physiology of the excretion of the nucleotide (28) . This expression (nanomoles per 100 ml GF) avoids entirely the inadequacies of alternate expressions and provides a parametric index of UcAMP in a variety of clinical situations, including mild to moderate renal impairment. A key feature of this expression is its functional specificity, for, in our experience, the only condition (other than hyperparathyroidism) associated with a "true" increase in UcAMP is pheochromocytoma (29) . This specificity is not unexpected, in that: (a) the urinary excretion of cAMP is an insensitive index of altered rates of cAMP production in the extracellular pool, due to the wide distribution and rapid tumover of the nucleotide in this pool (28, 29) , (b) in contrast, the excretion of cAMP provides a rapid and sensitive index of altered rates of production of the nucleotide in the nephrogenous pool (9, 10) , and (c) the relationship between NcAMP and circulating PTH in vivo appears to be specific (29 Table II and Fig. 5 ). However, this potential problem clearly becomes significant at levels of GFR in the range of 10 ml/min, and this important area requires more detailed investigation. For the sake of brevity and because the collections were less well controlled, the results of the 24-h cAMP analyses were not emphasized in this series. However, these results were virtually superimposable with those obtained during the clearance periods (see Tables I  and II) , and the determination of the 24-h excretion of cAMP may be preferable for some laboratories and(or) under certain clinical or experimental conditions. In addition, although modest physical activity has a slight but significant influence on plasma cAMP concentrations, such activity has a minimal influence in the results of total UcAMP and does not appear to require control for routine clinical interpretation of these results.
Clinical spectrum of parathyroid disease. The large prospective experience with 10 HPT provided by this series encompassed the entire clinical spectrum of the disease and was essential in evaluating the significance of several potential problems which might interfere with the cAMP analyses on their interpretation. First, with regard to the conflicting reports concerning posssible direct inhibitory effects ofhigh extracellular calcium concentrations on the activity of the PTH-sensitive renal adenylate cyclase system (20, 48, 49) , it was of interest that there was a positive, rather than a negative, correlation between serum calcium and NcAMP in the patients with 10 HPT. Second, our data confirmed the previously reported low UcAMP and reduced cAMP response capacity (to endogenous PTH) in patients with renal impair-ment (11. 12, 19 ); yet the parametric expression of both NcAMP and UcAMP as a function of GFR provided an excellent index of parathyroid status over the range of GFR encountered in this series. Finally, other clinical variables (e.g., diurnal changes, medications, etc.) did not appear to exert a discernible influence on the cAMP results.
The inclusion in this series of the kindred which was "biochemically normal" could be questioned, and the results in these five patients clearly influenced the apparent diagnostic potential of the various parameters which were compared. However, these patients fulfilled one set of criteria in a prospective study and could not, therefore, be excluded. This kindred has been reported separately as an example of "familial hypocalciuric hypercalcemia" (50) and represents an as yet undefined variant of hypercalcemia and(or) hyperparathyroidism similar to that of another kindred reported in the literature (51) . The other patients in this series with familial hyperparathyroidism or multiple endocrine neoplasia (types I and II) were clearly biochemically abnormal (patients 25, 28, 34, and 35, Table II ).
In addition to the hyperparathyroid patients included in this series, we have studied several patients suspected of having hypoparathyroidism on the basis of modest depressions in serum calcium and elevations in serum phosphorous. As might be anticipated, measurements of NcAMP in these patients overlapped with the low-normal range (i.e., values up to 1 nmol/100 ml GF were seen).
In five patients with nonparathyroid hypercalcemia, NcAMP averaged 0.26 nmol/100 ml GF (range: nondetectable to 0.40 nmol/100 ml GF), and plasma iPTH averaged 31 ,uleq/ml (range: nondetectable to 56 /Aleq/ml). In three patients with apparent "ectopic hyperparathyroidism", NcAMP averaged 4.57 nmol/ 100 ml GF (range: 3.97 to 5.32 nmol/100 ml GF), and plasma iPTH averaged 51 ,uleq/ml (range: 49 to 52 ,uleq/ml).
